FDA Issues Emergency Use Authorization for Negasunt Powder Against New World Screwworm
Summary
FDA issued an Emergency Use Authorization on April 27, 2026, for Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) to prevent and treat New World screwworm (NWS) myiasis. The EUA covers cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. FDA concluded the known and potential benefits outweigh the risks based on available scientific evidence.
“The FDA has concluded that based on the scientific evidence available, it is reasonable to believe that Negasunt Powder may be effective for the prevention and treatment of NWS myiasis in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids (e.g., mules), and captive wild, exotic, and zoo mammals, and that the known and potential benefits of the product outweigh its known and potential risks.”
About this source
GovPing monitors USDA APHIS News Releases for new agriculture & food safety regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 11 changes logged to date.
What changed
FDA issued an Emergency Use Authorization for Negasunt Powder, a topical powder containing coumaphos, propoxur, and sulfanilamide, for the prevention and treatment of New World screwworm (NWS) myiasis. The EUA expands treatment options to cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. FDA concluded based on scientific evidence that the known and potential benefits of the product outweigh its known and potential risks.
Livestock producers, veterinarians, and wildlife facility managers in affected regions should be aware that Negasunt Powder is now available under EUA for NWS treatment. Zoo operators and wildlife rehabilitators working with exotic or wild mammals should confirm their species are covered under the authorization and coordinate with FDA or USDA for access to the product.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FDA Issues Emergency Use Authorization for Topical Powder to Prevent and Treat New World Screwworm in Multiple Species
Print Washington, D.C., April 27, 2026 —Today, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for the prevention and treatment of New World screwworm (NWS) infestations (myiasis).
The FDA has concluded that based on the scientific evidence available, it is reasonable to believe that Negasunt Powder may be effective for the prevention and treatment of NWS myiasis in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids (e.g., mules), and captive wild, exotic, and zoo mammals, and that the known and potential benefits of the product outweigh its known and potential risks.
Mentioned entities
Related changes
Get daily alerts for USDA APHIS News Releases
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USDA APHIS.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USDA APHIS News Releases publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.